Moreover, based on the findings that IGF-2 and miR-483 are a promising translational research area for tumor therapy, the pharmacological inhibition of mitogenic signaling by targeting these molecules could be a challenge for pterygium treatment. Here, IGF2 is linked to neoplasm.